| 2019 | | 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea | 김대중 |
| 2021 | | 2021 clinical practice guidelines for diabetes mellitus in Korea | 김대중 |
| 2023 | | 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association | 김대중, 김혜진 |
| 2021 | | Acute glucose shift induces the activation of the nlrp3 inflammasome in thp-1 cells | 강엽, 김대중, 김혜진, 이관우, 한승진 |
| 2023 | | Amphiregulin Induces iNOS and COX-2 Expression through NF- κ B and MAPK Signaling in Hepatic Inflammation | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
| 2021 | | Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF- κ B, MKK7/JNK, and JAK2/STAT1 Signalling Pathways | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
| 2022 | | Association between Metabolically Healthy Obesity and Subclinical Atherosclerosis in the Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) Cohort | 김대중, 하경화 |
| 2022 | | Association Between Social Network and Cognitive Function: A Cross-Sectional Assessment From the Cardiovascular and Metabolic Diseases Etiology Research Center Cohort (2013–2018) | 김대중 |
| 2021 | | Association between social network structure and physical activity in middle-aged Korean adults | 김대중 |
| 2022 | | Association of prediabetes with death and diabetic complications in older adults: The pros and cons of active screening for prediabetes | 김대중, 하경화 |
| 2020 | | Association of social network size and composition with physical activity in Korean middle-aged adults | 김대중 |
| 2022 | | Associations between non-alcoholic fatty liver disease and cognitive impairment and the effect modification of inflammation | 김대중 |
| 2020 | | Associations between social network properties and metabolic syndrome and the mediating effect of physical activity: findings from the Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) Cohort | 김대중 |
| 2023 | | Associations of updated cardiovascular health metrics, including sleep health, with incident diabetes and cardiovascular events in older adults with prediabetes: A nationwide population-based cohort study | 김대중, 하경화, 한승진 |
| 2020 | | Body mass index and cardiovascular outcomes in patients with acute coronary syndrome by diabetes status: the obesity paradox in a Korean national cohort study | 김대중, 하경화 |
| 2020 | | Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study | 김대중, 하경화 |
| 2022 | | Cardiovascular disease in patients with type 2 diabetes | 김대중, 전자영 |
| 2021 | | Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data | 김대중 |
| 2021 | | Cardiovascular safety of sodium glucose cotransporter 2 inhibitors as add-on to metformin monotherapy in patients with type 2 diabetes mellitus | 김대중, 전자영, 하경화 |
| 2020 | | CCL20 induced by visfatin in macrophages via the NF-kappaB and MKK3/6-p38 signaling pathways contributes to hepatic stellate cell activation | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진 |
| 2022 | | Characteristics and Clinical Course of Diabetes of the Exocrine Pancreas: A Nationwide Population-Based Cohort Study | 김대중, 김혜진, 이관우, 이나미, 전자영, 한승진 |
| 2019 | | Characterization of variable presentations of diabetic ketoacidosis based on blood ketone levels and major society diagnostic criteria: a new view point on the assessment of diabetic ketoacidosis | 김대중, 전자영 |
| 2019 | | Circulating calcium levels and the risk of type 2 diabetes: a systematic review and meta-analysis | 김대중 |
| 2020 | | Clinical Outcomes of COVID-19 Patients with Type 2 Diabetes: A Population-Based Study in Korea | 김대중 |
| 2019 | | Cohort Profile: The Cardiovascular and Metabolic Diseases Etiology Research Center Cohort in Korea | 김대중, 하경화 |
| 2019 | | Diabetes and the Risk of Infection: A National Cohort Study | 김대중, 김은진, 최영화, 하경화 |
| 2019 | | Diabetes Fact Sheets in Korea, 2018: An Appraisal of Current Status | 김대중, 하경화 |
| 2023 | | Diabetes screening in South Korea: a new estimate of the number needed to screen to detect diabetes | 김대중, 하경화 |
| 2020 | | Diabetic Retinopathy and Related Clinical Practice for People with Diabetes in Korea: A 10-Year Trend Analysis | 김대중, 이기황, 정유리, 하경화 |
| 2023 | | Diet quality partially mediates the association between ultraprocessed food consumption and adiposity indicators | 김대중, 하경화 |
| 2021 | | Effect of teneligliptin versus sulfonylurea on major adverse cardiovascular outcomes in people with type 2 diabetes mellitus: A real-world study in Korea | 김대중, 하경화 |
| 2021 | | Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study | 김대중, 이나미, 하경화, 한승진 |
| 2024 | | Effectiveness and safety of sodium–glucose cotransporter 2 inhibitors in Asian populations | 김대중, 하경화 |
| 2021 | | Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19 | 김대중 |
| 2020 | | Effects of cigarette smoking on blood lipids in Korean men: Cardiovascular and Metabolic Diseases Etiology Research Center cohort | 김대중 |
| 2019 | | Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study | 김대중, 이기황, 정유리, 하경화 |
| 2023 | | Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study | 김대중, 하경화 |
| 2023 | | Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia | 김대중, 하경화 |
| 2023 | | Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study | 김대중, 하경화 |
| 2022 | | Empagliflozin Reduces the Progression of Hepatic Fibrosis in a Mouse Model and Inhibits the Activation of Hepatic Stellate Cells via the Hippo Signalling Pathway | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
| 2021 | | Erratum: Trends in cardiovascular complications and mortality among patients with diabetes in South Korea | 김대중, 하경화 |
| 2019 | | GLP1 improves palmitateinduced insulin resistance in human skeletal muscle via SIRT1 activity | 강엽, 김대중, 김혜진, 이관우, 전자영, 최성이, 한승진 |
| 2022 | | Healthcare resource utilization in patients treated with empagliflozin in East Asia | 김대중, 하경화 |
| 2022 | | Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
| 2020 | | Hypoglycemia and Dementia Risk in Older Patients with Type 2 Diabetes Mellitus: A Propensity-Score Matched Analysis of a Population-Based Cohort Study | 김대중, 김혜진, 문소영, 이관우, 전자영, 한승진 |
| 2023 | | Impact of Post-Transplant Diabetes Mellitus on Survival and Cardiovascular Events in Kidney Transplant Recipients | 김대중, 김혜진, 박범희, 이관우, 전자영, 한승진 |
| 2019 | | Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus | 김대중 |
| 2022 | | Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study | 김대중, 하경화 |
| 2023 | | Long-term Effectiveness of the National Diabetes Quality Assessment Program in South Korea | 김대중, 하경화 |
| 2021 | | Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study | 김대중, 하경화 |
| 2023 | | Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study | 김대중 |
| 2022 | | Maintaining Physical Activity Is Associated with Reduced Major Adverse Cardiovascular Events in People Newly Diagnosed with Diabetes | 김대중, 하경화 |
| 2020 | | Obesity Fact Sheet in Korea, 2019: Prevalence of Obesity and Abdominal Obesity from 2009 to 2018 and Social Factors | 김대중, 이관우 |
| 2022 | | Performance of Diabetes and Kidney Disease Screening Scores in Contemporary United States and Korean Populations | 김대중 |
| 2022 | | Prevalence and clinical characteristics of fulminant type 1 diabetes mellitus in Korean adults: A multi-institutional joint research | 김대중, 전자영 |
| 2022 | | Psychometric Properties of the Korean Version of the Perceived Therapeutic Efficacy Scale for Physical Activity in Adults With Type 2 Diabetes | 김대중, 김춘자 |
| 2022 | | Recommendation on an updated standardization of serum magnesium reference ranges | 김대중 |
| 2022 | | Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Cancer: A Population-Based Cohort Study Using a Common Data Model | 김대중, 박래웅 |
| 2022 | | Reply to “Recommendation on an updated standardization of serum magnesium reference ranges,” Jeroen H.F. de Baaij et al. | 김대중 |
| 2019 | | Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640-8) | 김대중, 이기황, 정유리, 하경화 |
